The meeting came as divisions grow in Europe over the proposed tariffs
President Joe Biden said on Tuesday that the United States would have enough vaccine for its entire adult population by the end of May, as he announced a deal for pharma giant Merck to produce the shot developed by rival Johnson & Johnson.
“This is the type of collaboration between companies we saw in World War II,” said Biden while announcing the pharmaceutical accord.
“We’re now on track to have enough vaccine supply for every adult in America by the end of May,” said the US leader — who previously targeted late July to amass sufficient doses to inoculate all Americans.
“That’s progress. Important progress. But it is not enough to have the vaccine supply,” Biden said, stressing that a “wartime effort” still lay ahead to administer the vaccines once acquired.
Merck will use two of its facilities to “produce drug substance, formulate and fill vials of J&J’s vaccine,” according to a Department of Health and Human Services (HHS) statement.
Biden’s administration will leverage the Defense Production Act to provide an initial $105 million for Merck to convert and equip its facilities to safely manufacture the vaccine, the statement said.
The J&J vaccine is the third to receive US regulatory approval for emergency use, but the first that requires a single shot as opposed to two jabs.
Biden also said Johnson & Johnson’s own vaccine manufacturing facilities “will now begin to operate 24/7” — at the administration’s urging.
The HHS said this would enable J&J to deliver close to 100 million doses to the US by end May — instead of June as previously pledged.
J&J said in a statement it was “pleased” to work with Merck, which will “enhance our production capacity so that we can supply beyond our current commitments”.
“Now is not the time to let up,” warned the president, calling on Americans to keep following social distancing protocols and wearing a mask even as new coronavirus cases fall and more are vaccinated.
“Great news, but stay vigilant,” Biden said. “It’s not over yet.”
The J&J shot appears slightly less protective than Pfizer and Moderna’s regimes, which have an efficacy of around 95 per cent against all forms of Covid-19. But all three have been shown to fully protect against hospitalisations and death.
A major vaccine producer in its own right, Merck had begun work on coronavirus vaccines, but abandoned those efforts in January, saying the immune responses that were “inferior” to successful Covid-19 vaccines.
The agreement between Merck and J&J follows on the heels of an accord between Pfizer/BioNTech and French pharma giant Sanofi, which plans to produce 125 million doses at a factory in Frankfurt, Germany after Sanofi’s own vaccine candidate fell short.
AFP
The meeting came as divisions grow in Europe over the proposed tariffs
Around 44% of total financing had a climate financing component
World Cup-winning coach Dav Whatmore asked the young boy to watch YouTube videos of his favourite batsman
Flare-up in Middle East tensions also supporting oil
Weekly jobless claims fall 12,000 to 219,000
Volkswagen said this month it needed to cut costs significantly
Many told the war revived traumas of past conflicts with some suffering panic attacks after hearing Israeli sonic booms or other loud bangs
Dubai’s real estate market continues to be a global hotspot